Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735368 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1ALOX15TDP1TP53 | |
| SCHEMBL3533847 | 0.85 | ALDH1A1 (0.35) | ALDH1A1TDP1TP53POLBKMT2A | |
| SCHEMBL13734501 | 0.83 | GPR119 (0.44) | SMN1; SMN2 | |
| SCHEMBL15511942 | 0.83 | GPR119 (0.44) | SMN1; SMN2 | |
| SCHEMBL13733872 | 0.80 | KDM4E (0.37) | KDM4EALDH1A1ALOX15TDP1TP53 | |
| SCHEMBL13735774 | 0.80 | GPR119 (0.32) | — | |
| SCHEMBL13733285 | 0.79 | — | — | |
| SCHEMBL26106336 | 0.79 | KDM4E (0.38) | KDM4EALDH1A1ALOX15TDP1TP53 | |
| Acetic Acid SCHEMBL2479619 | 0.76 | SLC1A3 (0.35) | KDM4EALDH1A1ALOX15 | |
| SCHEMBL12503814 | 0.76 | RBP4 (0.36) | ALDH1A1TP53POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | KDM4E 2379/4885ALDH1A1 1526/4885ALOX15 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.